Form 4: Lawrence T. Kennedy Jr. Acquires Convertible Preferred Stock in Biodesix Inc.

Lawrence T. Kennedy Jr., a director and 10% owner of Biodesix Inc., acquired Series A Non-Voting Convertible Preferred Stock, which is contingent on stockholder approval for conversion into common stock.

Summary

• Lawrence T. Kennedy Jr., a director and 10% owner of Biodesix Inc. (BDSX), filed a Form 4 indicating changes in beneficial ownership.
• On April 5, 2024, Kennedy acquired 43,478 shares of Series A Non-Voting Convertible Preferred Stock through a Perpetuity Trust UAD 6/30/16 and 65,218 shares through KFDI-B LLC.
• These preferred shares were issued under securities purchase agreements, contingent on stockholder approval at the 2024 annual meeting for conversion into common stock.
• Upon approval, each preferred share will convert into 40 common shares, subject to a 19.9% ownership limitation for Kennedy and his affiliates.
• The preferred stock has no expiration date.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of preferred stock by a director suggests confidence, but the conversion is contingent on stockholder approval, adding an element of uncertainty.

Positives

• The acquisition of preferred stock by a director and significant shareholder signals confidence in the company's future.
• The conversion of preferred stock into common stock, if approved, could increase the liquidity and trading volume of Biodesix Inc.'s common stock.

Risks

• Stockholder approval for the conversion of preferred stock into common stock is not guaranteed.
• The 19.9% ownership limitation could restrict Kennedy's ability to fully convert his preferred shares into common stock.

Future Outlook

The future depends on the stockholder approval of the conversion proposal at the 2024 annual meeting. If approved, the preferred stock will convert into common stock, potentially impacting the ownership structure and stock price.

Industry Context

Form 4 filings are standard disclosures for insiders, providing transparency into their transactions and potential alignment with company performance. The acquisition of convertible preferred stock can be seen as a strategic investment, especially when conversion is tied to future events.

Stakeholder Impact

• Shareholders: Potential dilution if the preferred stock is converted to common stock.
• Company: Potential increase in outstanding common stock if the conversion is approved.

Next Steps

• Biodesix Inc. will submit the conversion proposal to its stockholders for approval at the 2024 annual meeting.
• Stockholders will vote on the approval of the conversion of the Preferred Stock into shares of Common Stock.

Key Dates